Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
gene
reagent
sample publication
sample review
B2M
beta-2-microglobulin
total:5
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. 2008 to the paper
Dako anti-B2m was used to perform immunohistochemistry in order to study the presence of specific populations of tumor infiltrating lymphocytes in diagnostic primary melanoma biopsies are associated with outcome in clinically stage II melanoma patients. more
beta1 integrin
integrin subunit beta 1
total:85
Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. 2010 to the paper
Biolegend anti-CD29-FITC antibody was used to perform flow cytometry in order to study the properties induced by cell signaling by urokinase-type plasminogen activator receptor (uPAR) in breast cancer cells. more
BY55
CD160 molecule
total:1
A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-gamma protein expression in human monocytes and macrophages. 2008 to the paper
Abcam rabbit polyclonal anti-NK1 receptor antibody (ab466) was used in western blot to evaluate the effects of SP on PPAR-gamma protein expression in monocytes and macrophages (MDMs: monocyte-derived macrophages) from healthy smokers and non-smokers.
C3
complement C3
total:12
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. 2011 to the paper
AbD serotec goat-anti-Human-C3 was used to perform ELISA in order to show that HIV glycan coat could be recognized by PGT antibody to neutralize HIV. more
CAR
CXADR Ig-like cell adhesion molecule
total:7
Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implications. 2008 to the paper
Santa Cruz Biochemicals rabbit monoclonal anti-CAR antibody (CAR H300) was used in immunohistochemistry to evaluate the clinical significance of CAR expression in endometrial adenocarcinoma in paraffin sections from human tumor. more
CD155
PVR cell adhesion molecule
CD16
Fc fragment of IgG receptor IIIa
total:42
Inhibition of NF-?B signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. 2010 to the paper
AbDSerotec PE-Cy5-conjugated anti-CD16 antibody was used to perform flow cytometry in order to study the role of the EPEC protein NleE in inhibiting NF-kappa B signaling in human dendritic cells. more
CD18
integrin subunit beta 2
total:23
CBFbeta is critical for AML1-ETO and TEL-AML1 activity. 2009 to the paper
eBioscience allophycocyanin (APC), phycoerythrin (PE), or PerCPcy5.5 conjugated anti Mac-1 (clone M1/70) antibody was used in flow cytometry in order to determine whether CBFbeta is required for AML1-ETO and TEL-AML1 activity more
CD19
CD19 molecule
total:62
Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. 2011 to the paper
Becton Dickinson anti-CD19 PE was used to perform flow cytometry in order to show that human long-term engrafting HSCs could be isolated with CD49f as a marker. more
CD200
CD200 molecule
total:2
Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. 2007 to the paper
Cedarlane Laboratories CD200 antibody was used in immunohistochemistry at 1:200 dilution to study the role of CD200-CD200R pathway in axonal protection in the setting of inflammation-mediated neurodegeneration. more
CD200R1
CD200 receptor 1
total:1
Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. 2007 to the paper
Serotec CD200R antibody was used in immunohistochemistry at 1:100 dilution to study the role of CD200-CD200R pathway in axonal protection in the setting of inflammation-mediated neurodegeneration.
CD226
CD226 molecule
CD247
CD247 molecule
total:68
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. 2012 to the paper
eBioscience anti-human CD3 was used to perform blocking or activating experiments in order to show that cancer cell depended on glycine for rapid proliferation. more
CD3
CD3d molecule
total:43
CD4CD8?? lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. 2014 to the paper
eBioscience anti-CD3 antibody was used to perform cell culture in order to study how gut microbiota regulate immunesystem. more
CD34
CD34 molecule
total:79
Inhibition of NF-?B signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. 2010 to the paper
AbDSerotec PE-Cy5-conjugated anti-CD34 antibody was used to perform flow cytometry in order to study the role of the EPEC protein NleE in inhibiting NF-kappa B signaling in human dendritic cells. more
CD3E
CD3e molecule
total:20
Sialyllactose in viral membrane gangliosides is a novel molecular recognition pattern for mature dendritic cell capture of HIV-1. 2012 to the paper
eBioscience anti-CD3 monoclonal antibody OKT3 was used to stimulate CD4+ T cell in order to study novel HIV-1 capture mechanism. more
CD3G
CD3g molecule
total:48
A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. 2010 to the paper
eBioscience anti-CD3 antibody was used to perform immunocytochemistry and flow cytometry in order to show that mesenchymal stem cell can be polarized by downstream TLR signaling into two distinctly acting phenotypes. more
CD40
CD40 molecule
total:40
The germinal center kinase TNIK is required for canonical NF-?B and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor. 2012 to the paper
Santa Cruz Biotechnology anti-CD40 (C-20) monoclonal antibody was used to perform western blot in order to study TNIK plays what role and how it play this role for canonical NF-kB and JNK signaling in B-cells. more
CD40 ligand
total:13
Monocyte chemoattractant protein 1 and CD40 ligation have a synergistic effect on vascular endothelial growth factor production through cyclooxygenase 2 upregulation in gastric cancer. 2008 to the paper
Santa Cruz anti-CD40L antibody (1:200) was used to perform immunohistochemistry in order to study the effect of MCP1 and CD40 ligation on VEGF production. more
CD62L
selectin L
total:14
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. 2010 to the paper
BD Biosciences anti-CD62L antibody was used in flow cytometry in order to investigate the roles of Fas ligand and TRAIL in the regulation of murine thymic graft-versus-host disease. more
CD81
CD81 molecule
total:8
Fas death receptor enhances endocytic membrane traffic converging into the Golgi region. 2009 to the paper
BD Biosciences CD81 was used in immunocytochemistry in order to study the mechanism of endocytic membrane traffic converging into the golgi region more
CD8A
CD8a molecule
total:96
CD4CD8?? lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. 2014 to the paper
Becton Dickinson anti-CD8a antibody was used to perform flow cytometry in order to study how gut microbiota regulate immunesystem. more
CD8B
CD8b molecule
total:5
CD4CD8?? lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. 2014 to the paper
Becton Dickinson anti-CD8b antibody was used to perform flow cytometry in order to study how gut microbiota regulate immunesystem. more
CD96
CD96 molecule
CRTAM
cytotoxic and regulatory T cell molecule
DAP10
hematopoietic cell signal transducer
DAP12
transmembrane immune signaling adaptor TYROBP
E-cadherin
cadherin 1
total:129
TRAF4 is a novel phosphoinositide-binding protein modulating tight junctions and favoring cell migration. 2013 to the paper
Invitrogen rat anti-E-Cadherin (ECCD-2; 13-1900) was used to perform western blot in order to study the role for TRAF4, a novel phosphoinositide-binding protein in modulating tight junctions and promoting cell migration. more
FCGR2B
Fc fragment of IgG receptor IIb
total:6
Loss of CD103+ intestinal dendritic cells during colonic inflammation. 2010 to the paper
BD Pharmingen CD32 antibody was used for FACS analysis in order to investigate possible differences in dendritic cells within intestinal tissue of mice before and after induction of colitis. more
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA E
major histocompatibility complex, class I, E
total:12
ESCRT-III governs the Aurora B-mediated abscission checkpoint through CHMP4C. 2012 to the paper
Serotec FITC-conjugated anti-MHC-I was used to perform flow cytometry in order to show that cell abscission mediated by Aurora B was regulated by ESCRT-III. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-F
major histocompatibility complex, class I, F
total:1
Progressive myopathy and defects in the maintenance of myotendinous junctions in mice that lack talin 1 in skeletal muscle. 2008 to the paper
Sigma mouse monoclonal MHCf antibody was used in immunohistochemistry in order to study the role of talin 1 in the development and function of skeletal muscle
ICAM-1
intercellular adhesion molecule 1
total:30
Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by super-resolution microscopy. 2011 to the paper
R&D systems anti-ICAM-1 antibody was used to perform immunocytochemistry in order to study the remodelling of cortical actin at natural killer cell immune synapses. more
ICAM2
intercellular adhesion molecule 2
total:2
ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. 2008 to the paper
R&D Systems anti-ICAM-2 antibody was used for western blot in order to investigate the role of ICAM-2 in the mediation of membrane-actin link in neuroblastoma. more
ICAM4
intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)
IFITM1
interferon induced transmembrane protein 1
total:1
Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. 2010 to the paper
Proteintech Group anti-IFITM1 antibody was used to perform immunoblot in order to study the interaction between MUC1-C and STAT1 pathway in poor prognosis human breast cancers.
intercellular adhesion molecule 3
total:8
Binding of the Streptococcus gordonii DL1 surface protein Hsa to the host cell membrane glycoproteins CD11b, CD43, and CD50. 2008 to the paper
R&D Systems anti-CD50 (1:250) antibody was used in western blotting in order to investigate the binding of the Streptococcus gordonii DL1 surface protein Hsa to the host cell membrane glycoproteins CD11b, CD43, and CD50 more
ITGA4
integrin subunit alpha 4
total:7
Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. 2009 to the paper
eBioscience antibodies against alpha4beta1 were used in immunohistochemistry to investigate MuPAR and plasmin in the regulation of the proliferation, marrow pool size, homing, engraftment, and mobilization of HSPCs and HSCs. more
JAML
junction adhesion molecule like
KIR2DL1
killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1
KIR2DL2
killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2
KIR2DL4
killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4
KIR2DS1
killer cell immunoglobulin like receptor, two Ig domains and short cytoplasmic tail 1
KIR3DL1
killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1
KIR3DL2
killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2
KLRG1
killer cell lectin like receptor G1
total:1
KLRG1 binds cadherins and preferentially associates with SHIP-1. 2007 to the paper
eBioscience KLRG1 antibody was used in western blot and immunoprecipitation to demonstrate that KLRG1 differentially regulates NK cell and T cell functions.
LFA-1
integrin subunit alpha L
total:14
Altered gene expression in early atherosclerosis is blocked by low level apolipoprotein E. 2008 to the paper
eBioscience CD11a antibody was used in immunohistochemistry in order to study the linkage between changes of adhesion molecules/cofactors and atherosclerosis more
LILRA1
leukocyte immunoglobulin like receptor A1
LILRB1
leukocyte immunoglobulin like receptor B1
total:2
Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. 2006 to the paper
Upstate CD85j antibody was used in western blot to study the association of ILT2 and murine MHC class I molecules in vivo. more
LILRB2
leukocyte immunoglobulin like receptor B2
LILRB3
leukocyte immunoglobulin like receptor B3
LILRB4
leukocyte immunoglobulin like receptor B4
LILRB5
leukocyte immunoglobulin like receptor B5
MADCAM1
mucosal vascular addressin cell adhesion molecule 1
total:2
Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. 2005 to the paper
Oncogene Research Products monoclonal antibody against human MAdCAM-1 was used in western blot to study the mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. more
MICB
MHC class I polypeptide-related sequence B
total:1
Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. 2008 to the paper
R&D Systems anti-MICB antibody was used to perform flow cytometry in order to study the differential effects of IFN-alpha and IFN-gamma on tumor cells.
NKG2A
killer cell lectin like receptor C1
total:1
Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by super-resolution microscopy. 2011 to the paper
R&D systems anti-NKG2A antibody was used to perform immunocytochemistry in order to study the remodelling of cortical actin at natural killer cell immune synapses.
NKG2D
killer cell lectin like receptor K1
total:5
NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. 2010 to the paper
BD Pharmingen monoclonal anti-NKG2D-allophycocyanin antibody was used to perform flow cytometry in order to show multiple CD3 Zeta-dependent receptor functions can be impaired simultaneously by pathological NKG2D ligand expression. more
NECTIN2
nectin cell adhesion molecule 2
RAET1E
retinoic acid early transcript 1E
TRB
T cell receptor beta locus
total:7
Potential roles of a special CD8 alpha alpha+ cell population and CC chemokine thymus-expressed chemokine in ovulation related inflammation. 2009 to the paper
BD Bio Sciences TcR antibody was used in flow cytometry in order to study the effect of ovarian CD8alphaalpha+ cells and CC chemokine TECK on the ovulation-related inflammation. more
ULBP1
UL16 binding protein 1
ULBP3
UL16 binding protein 3
total:1
Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. 2008 to the paper
R&D Systems anti-ULBP3 antibody was used to perform flow cytometry in order to study the differential effects of IFN-alpha and IFN-gamma on tumor cells.
VCAM-1
vascular cell adhesion molecule 1
total:19
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. 2009 to the paper
Immunotech anti-VCAM-1 antibody was used in blocking or activating expriments to study the role for prostate specific membrane antigen in regulating the expression of IL-6 and CCL5 in prostate tumour cells. more